Peripheral Vascular Devices Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Market Size (2025) | USD 13.92 Billion |
| Market Size (2030) | USD 17.29 Billion |
| Growth Rate (2025 - 2030) | 4.43% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Peripheral Vascular Devices Market Analysis by Mordor Intelligence
The peripheral vascular devices market size reached USD 13.92 billion in 2025 and is on course to attain USD 17.29 billion by 2030, advancing at a 4.43% CAGR. Stable growth rests on higher procedure volumes fueled by global population aging, rising diabetes prevalence, and broader recognition of peripheral artery disease (PAD) as a cardiovascular risk equivalent. Regulatory friction under the European Union Medical Device Regulation (EU-MDR) slows new product approvals, but technology innovation—especially artificial intelligence (AI)–guided imaging and robotic catheter systems—continues to improve clinical efficiency. Consolidation among large manufacturers accelerates access to differentiated technologies such as intravascular lithotripsy, while outpatient migration of revascularization procedures supports cost-effective care delivery. Against this backdrop, the peripheral vascular devices market continues to favor products that demonstrate durable clinical outcomes and economic value to payers and providers.
Key Report Takeaways
By product type, peripheral vascular stents held 78.64% of the peripheral vascular devices market share in 2024, while atherectomy devices are forecast to expand at a 16.67% CAGR to 2030.
By end user, hospitals controlled 60.06% revenue in 2024; ambulatory surgical centers are projected to grow at 17.45% CAGR through 2030 as procedural migration to outpatient settings accelerates.
By geography, North America commanded 42.45% revenue share in 2024, whereas Asia-Pacific is set to record a 17.94% CAGR through 2030, reflecting rapid infrastructure expansion and regulatory harmonization.
Global Peripheral Vascular Devices Market Trends and Insights
Driver Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of PAD & CVD | +1.2% | Global, with highest impact in North America & Europe | Long term (≥ 4 years) |
| Ageing population & diabetes comorbidity | +0.9% | Global, particularly APAC and North America | Long term (≥ 4 years) |
| Adoption of minimally-invasive endovascular procedures | +0.8% | North America & EU, expanding to APAC | Medium term (2-4 years) |
| Rapid advances in drug-coated balloons & stents | +0.7% | Global, led by North America and Europe | Medium term (2-4 years) |
| Shift to office-based labs & ASCs | +0.5% | North America primarily, emerging in Europe | Short term (≤ 2 years) |
| AI-guided imaging & robotics for complex lesions | +0.4% | North America & EU, selective APAC adoption | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence of PAD & CVD
PAD affects 113 million people worldwide and has grown 23.5% since 2010, directly expanding the peripheral vascular devices market. Diabetes multiplies PAD incidence 2–4 times, pushing intervention demand into younger cohorts. Disability-adjusted life-years attributable to PAD have climbed 40% since 2010, pressuring health systems to prioritize early diagnosis and endovascular therapy. Clinical guidelines now align PAD risk with coronary artery disease, prompting insurers to maintain favorable reimbursement for revascularization procedures. Together, these epidemiological trends underpin enduring device demand across mature and emerging regions.
Ageing Population & Diabetes Comorbidity
Adults aged ≥ 65 years show PAD prevalence above 20% versus 4.3% in younger adults. Within this cohort, diabetes occurs in 26.8% of patients, escalating lesion calcification and necessitating premium atherectomy and lithotripsy devices. Aging also correlates with multi-vessel disease, spurring multi-device use per procedure. Payers increasingly endorse early intervention to avoid limb loss and downstream healthcare costs, sustaining procedural volume even when macroeconomic pressures constrain hospital budgets.
Adoption of Minimally-Invasive Endovascular Procedures
Endovascular techniques accounted for more than 80% of peripheral revascularizations in 2024 and continue to penetrate surgical bypass indications thanks to shorter recovery times and equivalent limb salvage outcomes. IQVIA projects 25% outpatient vascular procedure growth through 2028, aligning with payer incentives for site-of-service cost reduction. Drug-coated balloons deliver 92% freedom from clinically driven target-lesion revascularization at 12 months, reinforcing physician confidence. As device profiles broaden to smaller-diameter vessels, minimally invasive approaches attract previously ineligible patients, extending the peripheral vascular devices market.
Rapid Advances in Drug-Coated Balloons & Stents
Boston Scientific’s AGENT drug-coated balloon gained FDA clearance in March 2024 after demonstrating 82% primary patency at 12 months. Sirolimus-coated balloons with Breakthrough Device Designation promise lower restenosis risk in arteriovenous fistula indications. Evidence from real-world registries aligns with trial data, prompting payers to reimburse at premium price points. The result is a technology shift away from plain angioplasty, reinforcing revenue growth even as unit prices face pressure.
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Stringent regulatory & EU-MDR delays | -0.8% | Europe primarily, spillover to global markets | Medium term (2-4 years) |
| Device recalls & safety concerns | -0.6% | Global, with highest impact in North America & Europe | Short term (≤ 2 years) |
| High cost & reimbursement limits in EMs | -0.5% | Emerging markets, particularly Asia-Pacific & Latin America | Long term (≥ 4 years) |
| Nitinol alloy supply-chain vulnerability | -0.3% | Global manufacturing, concentrated supplier base | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Stringent Regulatory & EU-MDR Delays
EU-MDR lifted recertification requirements for legacy devices, leaving 85% of prior CE-marked products uncertified as of April 2024. Notified-body bottlenecks stretch review cycles to 18-36 months, delaying European launches and cascading into countries that rely on EU regulatory decisions. Compliance costs can exceed USD 2 million per product family, straining mid-size innovators and narrowing product lines in smaller indications.
Device Recalls & Safety Concerns
Peripheral device recalls rose 23% in 2024, dominated by manufacturing defects and long-term device-related events that triggered mandatory 483 warnings. Litigation over inferior vena cava filters resulted in settlements exceeding USD 2.5 billion, prompting physicians to prefer retrievable or short-dwell alternatives. Safety alerts extend beyond affected devices, generating caution for newer entrants until long-term data are available.
Segment Analysis
By Product Type: Stents Sustain Leadership While Atherectomy Drives Incremental Growth
Peripheral vascular stents dominated 78.64% of the peripheral vascular devices market in 2024 owing to proven durability across iliac, femoropopliteal, and infrapopliteal segments. Although stent adoption remains robust, atherectomy devices are projected to register a 16.67% CAGR to 2030 as calcified lesion prevalence rises within diabetic populations. The Golazo Peripheral Atherectomy System cleared by the Centers for Medicare & Medicaid Services exemplifies regulatory support for mechanical plaque removal innovations.
Atherectomy’s rapid growth does not eclipse established segments like percutaneous transluminal angioplasty (PTA) balloons, which retain procedural versatility and price advantages. Thrombectomy devices, validated by 99.1% limb-salvage rates in the THRIVE analysis, gain share in acute limb ischemia interventions. Vascular closure devices achieve 7.9% CAGR as same-day discharge protocols spread, while aortic stent grafts expand through adjunct technologies such as endo-anchors that accommodate hostile neck anatomies.
Note: Segment shares of all individual segments available upon report purchase
By End User: Ambulatory Surgical Centers Accelerate Yet Hospitals Retain Scale Advantage
Hospitals generated 60.06% of 2024 revenue, supported by intensive-care capability and multispecialty coordination. However, ambulatory surgical centers (ASCs) are forecast to grow at 17.45% CAGR, reflecting payer preference for lower cost sites and physician ownership interest. CMS approvals for outpatient use of drug-coated balloons and atherectomy systems reinforce this shift, positioning ASCs to capture an additional 12% volume share by 2030.
Specialty vascular clinics—often extensions of office-based labs—supplement ASC growth by focusing exclusively on limb salvage programs. Hospitals are responding through joint-venture outpatient centers and by integrating AI-enabled imaging suites to retain complex cases. Nonetheless, outpatient migration is irreversible, forcing manufacturers to refine distribution models that support small-batch, just-in-time inventory for dispersed facilities.
Geography Analysis
North America accounted for 42.45% of 2024 revenue on the strength of mature reimbursement systems and early adoption of AI-guided imaging that achieves 82% procedural precision. The United States drives growth through nearly 700 office-based labs expanding at 7.5% annually, while Canada leverages universal coverage to ensure broad access to endovascular therapy. The peripheral vascular devices market size in North America is expected to advance from USD 5.91 billion in 2025 to USD 6.99 billion by 2030.
Asia-Pacific is the fastest growing region at a 17.94% CAGR, fueled by middle-class expansion, capacity upgrades, and standards such as YY/T 1898-2024 that clarify hydrophilic-coating performance benchmarks. China’s volume-based procurement policy compresses unit prices yet balloons aggregate demand, allowing international and local players to scale manufacturing footprints. India’s Materiovigilance Programme increases post-market transparency, driving hospitals toward devices with proven safety data. Japan and South Korea remain early adopters of robotic catheter systems, anchoring premium-segment sales.
Europe sustains meaningful demand despite EU-MDR delays that slowed new-product turnover. Germany and France lead utilization, emphasizing evidence-based purchasing decisions that reward long-term outcome data. The United Kingdom’s post-Brexit regulatory pathway introduces parallel approval costs but retains high procedure volumes. South America and the Middle East & Africa represent emerging opportunities; Brazil and Saudi Arabia spearhead catheter-laboratory expansion, although reimbursement ceilings temper rapid uptake of premium devices. Overall, the peripheral vascular devices market continues to globalize, prompting manufacturers to regionalize supply chains and tailor portfolios to local economic realities.
Competitive Landscape
The peripheral vascular devices market demonstrates moderate consolidation layered over vigorous mid-tier competition. Johnson & Johnson closed its USD 13.1 billion acquisition of Shockwave Medical in August 2024, adding intravascular lithotripsy that targets calcified lesions refractory to balloon angioplasty. Boston Scientific followed with a USD 1.16 billion takeover of Silk Road Medical, securing the TCAR platform for stroke-prevention carotid interventions. Abbott deepened its thrombectomy presence by buying Walk Vascular and the JETi AIO aspiration system.
Large strategics harness these deals to assemble end-to-end vascular portfolios that align with value-based reimbursement. Smaller innovators such as Amplitude Vascular Systems progress through Investigational Device Exemption studies for Pulse Intravascular Lithotripsy, challenging incumbents in the calcified-lesion niche. AI-enabled imaging start-ups partner with stent manufacturers to embed software algorithms into procedural workflows, offering holistic solutions that improve cath-lab productivity.
Competition increasingly revolves around generating real-world evidence that links device use to reduced reintervention rates and total-episode costs. Companies invest in post-market registries compliant with EU-MDR surveillance mandates, turning regulatory burden into data-driven competitive advantage. Pricing remains under pressure from hospital procurement groups and Asia-Pacific tender systems, yet differentiated technologies that shorten procedure time or eliminate staged interventions command premium margins and insulate manufacturers from commoditization.
Peripheral Vascular Devices Industry Leaders
-
Abbott Laboratories
-
Boston Scientific Corporation
-
Becton, Dickinson and Company
-
Medtronic
-
Cook
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- January 2025: Boston Scientific completed its USD 664 million purchase of Bolt Medical, adding complementary intravascular lithotripsy capabilities
- May 2024: Johnson & Johnson finalized its USD 13.1 billion acquisition of Shockwave Medical, securing proprietary lithotripsy technology
Global Peripheral Vascular Devices Market Report Scope
As per the scope of the report, vascular devices can be referred to as medical devices which are utilized in the case of catheterization post cardiovascular surgery, for the closure and achieving hemostasis in the artery. The peripheral vascular devices market is segmented by device type (peripheral vascular stents, peripheral transluminal angioplasty (PTA) balloon catheters, peripheral transluminal angioplasty (PTA) guidewires, atherectomy devices, embolic protection devices, inferior vena cava filters, and other device types) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| siRNA |
| miRNA |
| shRNA |
| Other RNA molecules |
| Therapeutics | Oncology |
| Cardiometabolic Disorders | |
| Infectious Diseases | |
| Neurological Disorders | |
| Rare Genetic Disorders | |
| Drug Discovery & Screening | |
| Diagnostics | |
| Agriculture | |
| Other Applications |
| Lipid Nanoparticles | Ionizable LNPs |
| Liposomes | |
| Polymer & Conjugate Systems | GalNAc Conjugates |
| PEGylated Carriers | |
| Viral Vectors | Adeno-associated Virus |
| Lentiviral Vectors | |
| Physical Delivery Methods | |
| Emerging Nanomaterials (Exosomes, Metal-oxide, etc.) |
| Pharmaceutical & Biotechnology Companies |
| Contract Development & Manufacturing Organizations (CDMOs) |
| Academic & Research Institutes |
| Diagnostic Laboratories |
| Agricultural Biotechnology Firms |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| India | |
| Japan | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| South America | Brazil |
| Argentina | |
| Rest of South America | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa |
| By Molecule Type (Value) | siRNA | |
| miRNA | ||
| shRNA | ||
| Other RNA molecules | ||
| By Application (Value) | Therapeutics | Oncology |
| Cardiometabolic Disorders | ||
| Infectious Diseases | ||
| Neurological Disorders | ||
| Rare Genetic Disorders | ||
| Drug Discovery & Screening | ||
| Diagnostics | ||
| Agriculture | ||
| Other Applications | ||
| By Delivery Technology (Value) | Lipid Nanoparticles | Ionizable LNPs |
| Liposomes | ||
| Polymer & Conjugate Systems | GalNAc Conjugates | |
| PEGylated Carriers | ||
| Viral Vectors | Adeno-associated Virus | |
| Lentiviral Vectors | ||
| Physical Delivery Methods | ||
| Emerging Nanomaterials (Exosomes, Metal-oxide, etc.) | ||
| By End User (Value) | Pharmaceutical & Biotechnology Companies | |
| Contract Development & Manufacturing Organizations (CDMOs) | ||
| Academic & Research Institutes | ||
| Diagnostic Laboratories | ||
| Agricultural Biotechnology Firms | ||
| By Geography (Value) | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| India | ||
| Japan | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
What is the current value of the peripheral vascular devices market?
The peripheral vascular devices market size stands at USD 13.92 billion in 2025 and is forecast to reach USD 17.29 billion by 2030.
Which product category generates the most revenue?
Peripheral vascular stents held 78.64% of 2024 revenue, reflecting broad clinical acceptance.
Which segment is expected to grow the fastest through 2030?
Atherectomy devices are projected to register a 16.67% CAGR thanks to rising calcified-lesion prevalence.
Why are ambulatory surgical centers gaining share?
Payers favor lower procedure costs in outpatient settings, driving a projected 17.45% CAGR for ASCs through 2030.
Which region offers the highest growth potential?
Asia-Pacific leads with an expected 17.94% CAGR as infrastructure investments and regulatory harmonization accelerate adoption.
How are AI and robotics influencing procedural outcomes?
AI-guided imaging achieves 82% precision and 94% recall, while robotic navigation lowers radiation exposure and standardizes complex interventions.
Page last updated on:
